Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 7/20 | 1.00 |
| ▸ | MAOB | P27338 | 4/20 | 0.84 |
| ▸ | IDO1 | P14902 | 4/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.50 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | HTR1A | P08908 | 1/20 | 0.50 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.50 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | HTR3A | P46098 | 1/20 | 0.50 |
| ▸ | BACE1 | P56817 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4369846 | 0.98 | TAAR1 (0.95) | TAAR1MAOBIDO1 | |
| Iodide SCHEMBL28689118 | 0.98 | TAAR1 (0.95) | TAAR1MAOBIDO1CYP1A2CYP2A6 | |
| Bromide SCHEMBL28801000 | 0.98 | TAAR1 (0.95) | TAAR1MAOBIDO1CYP1A2CYP2A6 | |
| Hydrochloric Acid SCHEMBL30558891 | 0.92 | MAOB (1.00) | TAAR1MAOBIDO1 | |
| SCHEMBL2872345 | 0.88 | TAAR1 (0.78) | TAAR1MAOBIDO1 | |
| SCHEMBL31377022 | 0.88 | TAAR1 (0.78) | TAAR1MAOBIDO1CYP1A2KDM4E | |
| Hydrochloric Acid SCHEMBL17042516 | 0.87 | TAAR1 (0.75) | TAAR1MAOBIDO1 | |
| Acetic Acid SCHEMBL29202185 | 0.87 | TAAR1 (0.75) | TAAR1MAOBIDO1 | |
| SCHEMBL2025850 | 0.86 | TAAR1 (0.76) | TAAR1MAOBIDO1 | |
| SCHEMBL7777613 | 0.85 | TAAR1 (0.72) | TAAR1MAOBLOXL2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 573 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119371337-A | Metal halide perovskite nanocrystalline resistant to heat-induced fluorescence quenching, and preparation method and application thereof | 华南理工大学 | 2025-01-28 | — | — | CN | claimed |
| CN-118513552-A | Preparation process of low-agglomeration nanometer copper powder and nanometer copper powder | 隆基绿能科技股份有限公司 | 2024-08-20 | — | — | CN | claimed |
| CN-116813497-B | Amide compound and preparation method, pharmaceutical composition and application thereof | 天津匠新致成科技有限公司 | 2023-11-14 | — | — | CN | claimed |
| CN-116444454-B | N-hydroxy amidine derivative, preparation method and application thereof, and tumor immunotherapy medicament | 中国医学科学院医药生物技术研究所 | 2023-09-12 | — | — | CN | claimed |
| CN-116444454-A | N-hydroxy amidine derivative, preparation method and application thereof, and tumor immunotherapy medicament | 中国医学科学院医药生物技术研究所 | 2023-07-18 | — | — | CN | claimed |
| CN-112457245-B | Synthesis method of 7- (trifluoromethyl) isoquinoline-5-amine | 苏州康润医药有限公司 | 2022-11-22 | — | — | CN | claimed |
| US-20220194969-A1 | METAL HALIDE PEROVSKITE LIGHT EMITTING DEVICE AND METHOD FOR MANUFACTURING SAME | SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION (KR) | 2022-06-23 | — | — | US | claimed |
| CN-110218206-B | Bisindolylmaleimide derivative and preparation method and application thereof | 中国海洋大学 | 2022-03-04 | — | — | CN | claimed |
| CN-113214236-B | Preparation method of thiophene bi-1, 3, 4-oxadiazole formamide compounds, products and application thereof | 南京林业大学 | 2022-01-04 | — | — | CN | claimed |
| CN-112457250-A | Broad-spectrum fluorescent substrate and preparation method and application thereof | 上海中医药大学 | 2021-03-09 | — | — | CN | claimed |
| US-7763618-B2 | 1-Pentyl-3-{6-[4-(2-trifluoromethylbenzoyl)piperazin-1-yl]-pyridin-3-yl}urea; inhibitors of stearoyl-CoA desaturase; cardiovascular disease, diabetes, obesity, metabolic syndrome | XENON PHARMACEUTICALS INC. (CA) | 2010-07-27 | — | — | US | claimed |
| US-20090131447-A1 | COMBINATION THERAPY | XENON PHARMACEUTICALS INC. (CA) | 2009-05-21 | — | — | US | claimed |
| CN-101410366-A | Substituted bicyclic ring derivatives and uses thereof | ASAHI KASEI PHARMA CORP (JP) | 2009-04-15 | — | — | CN | claimed |
| CN-101163504-A | Combination therapy | XENON PHARMACEUTICALS INC (CA) | 2008-04-16 | — | — | CN | claimed |
| EP-1846035-A2 | COMBINATION THERAPY | XENON PHARMACEUTICALS INC. (CA) | 2007-10-24 | — | — | EP | claimed |
| JP-2007500716-A | — | — | 2007-01-18 | — | — | JP | claimed |
| US-20060293308-A1 | Pyridyl derivatives and their use as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2006-12-28 | — | — | US | claimed |
| WO-2006086445-A2 | COMBINATION THERAPY | XENON PHARMACEUTICALS INC. (CA) | 2006-08-17 | — | — | WO | claimed |
| EP-1651605-A2 | PYRIDYL DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2006-05-03 | — | — | EP | claimed |
| WO-2005011654-A2 | PYRIDYL DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2005-02-10 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220194969-A1 | METAL HALIDE PEROVSKITE LIGHT EMITTING DEVICE AND METHOD FOR MANUFACTURING SAME | HCN4, SLC46A1, FES | TAAR1 4232/4885MAOB 880/4885IDO1 3820/4885 |
| US-20060293308-A1 | Pyridyl derivatives and their use as therapeutic agents | PRMT9, SNRPD3, PRDX5 | TAAR1 3878/4885MAOB 1532/4885IDO1 2457/4885 |
| US-20090131447-A1 | COMBINATION THERAPY | SCD, SCD5, ARG1 | TAAR1 2558/4885MAOB 3255/4885IDO1 1601/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.